Core Insights - The partnership between Richtech Robotics and Beijing City of Design Development Co., Ltd. aims to enhance AI integration with robotic solutions, focusing on service experiences in industries like hospitality, healthcare, and retail [2][3] - The collaboration will involve the establishment of a "Beijing Foreign-Invested R&D Center" to pursue advancements in domain-specific AI models, autonomous robotic decision-making systems, and integrated software-hardware platforms [7][2] - Richtech Robotics has deployed over 400 robotic solutions across various sectors in the U.S., including notable clients such as Texas Rangers' Globe Life Field and Hilton [3][4] Company Overview - Richtech Robotics specializes in collaborative robotic solutions for the service industry, aiming to transform customer experiences and enhance operational efficiency [4] - The company focuses on integrating advanced automation to improve interactions and drive innovation within organizations [4]

Total Revenue of $15.6 Million, a $5.7 Million or 58% Increase over Prior Year QuarterNet income of $0.9 Million, a $15.5 Million Increase over Prior Year QuarterAdjusted EBITDA of $4.0 Million, a $2.4 Million or 158% Increase over Prior Year QuarterTotal Fourth Quarter Direct Operating Margin of 55%LOS ANGELES, June 27, 2025 /PRNewswire/ -- Cineverse Corp. ("Cineverse" or the "Company") (NASDAQ: CNVS), a global streaming technology and entertainment company, today announced its financial results for its fo ...

BERKELEY HEIGHTS, N.J., June 27, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced the pricing of its previously announced underwritten public offering of 6,604,507 shares of its common stock. The total gross proceeds from the offering to the Company are expected to be approximately $85 million. In addition, CorMedix granted the underwriters a 30-day o ...

TORONTO, June 27, 2025 (GLOBE NEWSWIRE) -- Canadian Apartment Properties Real Estate Investment Trust (“CAPREIT”) (TSX:CAR.UN) announced today it will issue its financial results for the three and six months ended June 30, 2025 after markets close on: Thursday, August 7, 2025 A conference call to discuss the results will be hosted by the CAPREIT senior management team on: Friday, August 8, 2025 at 9:00 am ET The telephone numbers for the conference call are: Canadian Toll Free: +1 (833) 950-0062Internatio ...

Core Insights - Ultragenyx Pharmaceutical Inc. has received Breakthrough Therapy Designation from the FDA for GTX-102 as a treatment for Angelman syndrome [1][2] - The designation highlights the urgent need for effective treatments and the promising clinical results observed with GTX-102 [2] - The Phase 3 Aspire study is currently enrolling participants, with plans for an additional Aurora study to evaluate GTX-102 in other genotypes and ages expected to start later in 2025 [3] Company Overview - Ultragenyx is a biopharmaceutical company focused on developing therapies for serious rare and ultra-rare genetic diseases [7] - The company has a diverse portfolio of approved medicines and treatment candidates aimed at addressing high unmet medical needs [7] - Ultragenyx's management team has extensive experience in the development and commercialization of rare disease therapeutics [8] Product Information - GTX-102 (apazunersen) is an investigational antisense oligonucleotide therapy designed to reactivate expression of the UBE3A gene [4] - The therapy has received multiple designations from the FDA, including Orphan Drug Designation and Fast Track Designation [4] - The Phase 1/2 study demonstrated consistent developmental gains in 74 patients aged 4-17 with a full maternal UBE3A gene deletion [2] Angelman Syndrome Insights - Angelman syndrome is a rare neurogenetic disorder affecting approximately 60,000 people in commercially accessible geographies [5] - The disorder is characterized by cognitive impairment, motor impairment, and seizures, requiring continuous care for affected individuals [6] - There are currently no approved therapies for Angelman syndrome, but animal models suggest potential for symptom improvement at any age [6]

NOVI, Mich., June 27, 2025 (GLOBE NEWSWIRE) -- Gentherm (NASDAQ: THRM) a global market leader of innovative thermal management and pneumatic comfort technologies, today announced the expansion of its long-standing partnership with DUOMED into France. Building on years of successful collaboration in the Benelux region, this extension marks a strategic milestone as both companies work to deliver advanced patient temperature management technologies to more clinicians and patients across Europe. Under this agre ...

ZEELAND, Mich., June 27, 2025 (GLOBE NEWSWIRE) -- Gentex Corporation (NASDAQ: GNTX) announced today the launch of PLACE, a new smart home safety system now available for online and in-store purchase through a national big-box retailer. PLACE is a suite of advanced, multi-feature smoke and carbon monoxide alarms designed to enhance home safety, comfort, and security with room-specific functionality. Gentex has been a leader in fire protection and sensing technology for over 50 years. The launch of PLACE in t ...

Dairy Based Renewable Natural Gas from Seven Digesters Averages Negative 384 Carbon IntensityCUPERTINO, Calif., June 27, 2025 (GLOBE NEWSWIRE) -- Aemetis, Inc. (NASDAQ: AMTX), a renewable natural gas (RNG) and renewable fuels company, announced today that the California Air Resources Board (CARB) has approved provisional pathways under the Low Carbon Fuel Standard (LCFS) for seven dairy digesters built and operated by Aemetis Biogas, a subsidiary of the Company. The pathway approvals are effective as of Jan ...

Frøya, 27 June 2025: The annual general meeting of Kaldvík AS was held today on 27 June 2025 at 12:00 hours (CEST) with approximately 61.24% of all shares entitled to vote present either in person or by proxy. A copy of the minutes is attached to this announcement. All resolutions were approved in accordance with the proposal from the board of directors. For further information, please contact:Roy-Tore Rikardsen, CEO: +354 791 0006 (mobile)Robert Robertsson, CFO: +354 843 0086 (mobile) This information is s ...

SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- Leading shareholder rights law firm Johnson Fistel, PLLP announces an investigation into potential breaches of fiduciary duties by current and former directors and officers of Masimo Corporation (NASDAQ: MASI). The investigation centers on whether Masimo’s leadership failed to uphold their responsibilities to shareholders and may have violated corporate governance obligations. Why Is Johnson Fistel Investigating Masimo Corporation?The investigation follows a cour ...